Trial Profile

Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Docetaxel; Paclitaxel
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms AINO

Most Recent Events

11 Mar 2024 Results assessing the prognostic value of the VEGF family in patients treated for metastatic breast cancer published in the BMC Cancer
27 Mar 2019 Status changed from completed to discontinued. (Participants are no longer being examined. The results are published 2016 Anticancer Research 36: 6431-6438)
01 Dec 2016 Results published in the Anticancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com